Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2024

Data from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

FMFederica MigliettaMRMoira RagazziBFBethania Fernandes

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Miglietta et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522c8bhttps://doi.org/10.1158/1078-0432.c.6760515.v3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation study of tumor-infiltrating lymphocytes combined with residual cancer burden and prognosis in breast cancer patients receiving neoadjuvant chemotherapy2025
  2. 2Supplementary Figure 3 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer2024
  3. 3Supplementary Figure 3 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer2024
  4. 4Supplementary Figure 1 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer2024
  5. 5Supplementary Figure 1 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer2024